Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients.
Anti-hepatitis B virus (HBV) therapy leads to the emergence of mutant viral strains during the treatment of chronic hepatitis B with nucleos(t)ides analogues. The existence of HBV variants with primary antiviral resistance may be important for treatment choice. We studied two patients with chronic HBV infection by sequencing the HBV polymerase gene. They had adefovir- and tenofovir-related mutations in the viral polymerase, although they had never been treated. These mutations were rtV214A/rtN238T in one patient and rtA194T in the other. Thus, mutations in untreated patients deserve cautious surveillance. These data indicate that mutations that can theoretically confer adefovir or tenofovir resistance may emerge in treatment-naive patients.
Pastor
Rebecca
R
Institut de Virologie, 3 Rue Koeberle, 67000 Strasbourg, France.
Habersetzer
Francois
F
Fafi-Kremer
Samira
S
Doffoel
Michel
M
Baumert
Thomas-F
TF
Gut
Jean-Pierre
JP
Stoll-Keller
Francoise
F
Schvoerer
Evelyne
E
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D019943:Amino Acid Substitution; D000998:Antiviral Agents / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D014644:Genetic Variation; D006509:Hepatitis B / Q000188:drug therapy*; D006515:Hepatitis B virus / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000627:therapeutic use*; D000068698:Tenofovir; D014764:Viral Proteins / Q000235:genetics
D000998:Antiviral Agents; D063065:Organophosphonates; D014764:Viral Proteins; D019259:Lamivudine; C053001:adefovir; D000068698:Tenofovir; D000225:Adenine